N/A N=80 The Maternal and Perinatal Outcomes Associated With the Use of Non-pharmacological in Labor
Pain
Primary: Number of Participants Who Requested Analgesia During the Active Phase of Childbirth — 37; 35 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=16 A Study in Healthy Men and Women to Test Which Effects Memantine and BI 425809 Have on Each Other
Healthy
Primary: Area Under the Concentration-time Curve of the Analyte in Plasma at Steady State Over a Uniform Dosing Interval τ (BI 425809 + Memantine : BI 425809) — 9029.04; 8559.78…
N/A N=48 Translating Intensive Arm Rehabilitation in Stroke to a Telerehabilitation Format
Stroke · Hemiparesis
Primary: Wolf Motor Function Test Performance Time (WMFT) — 3.6; 2.9; 3.1 log (seconds) — p=0.64
Phase 3 N=479 Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease
Coronavirus · Acute Respiratory Infection · SARS-CoV Infection
Primary: COVID Outcomes Scale Score on Study Day 15 (14 Days After Randomization) — 6; 6 score on a scale
Phase 3 N=168 S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
Recurrent Non-Small Cell Lung Carcinoma · Stage IV Non-Small Cell Lung Cancer
Primary: 2-year Overall Survival Rate — 67; 70 percentage of participants — p=0.44
Phase 3 N=19 Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease
Covid-19
Primary: Number of Participants Who Achieved Clinical Response by Day 15 — 7; 7; 4 Participants
N/A N=31 Feasibility of Using sipIT Tools to Increase Compliance With Fluid Consumption Guidelines in Urolithiasis-Prone Subjects
Urolithiasis
Primary: Adherence to Intervention Assessed by Study Completion — 27 Participants
N/A N=58 Improving Self-Management in Adolescents With Sickle Cell Disease
Sickle Cell Disease
Primary: Scores on Behavioral Activation Measure at Baseline and 6 Weeks (Post-treatment) — 68.48; 69.13; 76.57; 68.82 score on a scale — p=.09
N/A N=25 Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers
HIV · Hepatitis C
Primary: Simeprevir AUC Pharmacokinetics — 30946; 30333 ng*h/mL
Phase 2 N=6 Minocycline to Treat Central Retinal Vein Occlusion
Retinal Vein Occlusion
Primary: The Primary Outcome is the Comparison Between the Minocycline and Placebo Groups of the Mean Change in Best-corrected Visual Acuity (BCVA) in the Study Eye at 12 Months…
Phase 2 N=62 Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
Depressive Disorder, Major · Depressive Disorder, Treatment-Resistant
Primary: Incidence of Treatment Emergent Adverse Events (AEs) [Safety and Tolerability] — 9; 15; 12; 0 Participants
Phase 2 N=141 Clinical Evaluation of Etafilcon A With Ketotifen
Visual Acuity
Primary: Monocular Contact Lens-corrected Distance Visual Acuity (Per-Protocol Population) — -0.111; -0.109; -0.115; -0.118 logMAR
Phase 3 N=762 Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer
Breast Cancer
Primary: Percentage of Participants With Disease-free Survival (DFS) — 78.97; 83.37 Percentage of participants — p=0.175
N/A N=150 The Effectiveness of Cancer Pain Management in Siriraj Outpatient Pain Clinic
Pain, Chronic · Cancer
Primary: Improvement of Pain. — 3 score on a scale (0-10)
Phase 2 N=9 Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer
Small Cell Lung Cancer · Small Cell Lung Cancer Extensive Stage
Primary: Phase I - Recommended Phase II Dose (RP2D) of 177Lu-DOTA0-Tyr3-Octreotate — 7.4 GBq